PUBLISHER: The Business Research Company | PRODUCT CODE: 1945236
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945236
Glaucoma surgery devices encompass a range of medical tools and instruments utilized for surgical interventions on the eye, aiming to address glaucoma. The objective of surgical procedures for glaucoma treatment is to enhance aqueous outflow capacity, ultimately reducing intraocular pressure and mitigating the risk of vision loss and blindness associated with glaucoma-a group of eye diseases that inflict damage to the optic nerve.
The primary categories of glaucoma surgery devices include drainage systems, laser-based devices, implants, and others, serving to address both open-angle and closed-angle glaucoma. Drainage systems involve catheters strategically positioned near the surgical site to evacuate any accumulated blood, pus, or fluid, preventing the buildup within the body. Various surgical techniques fall under this category, such as angle closure glaucoma surgery, aqueous shunt surgery, laser surgery, among others. Drainage systems, facilitating the removal of fluids, find application in diverse contexts, spanning conventional glaucoma surgeries to minimally invasive glaucoma surgeries. These devices cater to different end-users, including eye hospitals, ophthalmology clinics, and outpatient surgical centers.
Tariffs are impacting the glaucoma surgery devices market by increasing costs of imported surgical instruments, laser systems, implants, precision optics, and microfabricated components used in minimally invasive and conventional glaucoma procedures. Eye hospitals and ophthalmology clinics in North America and Europe are most affected due to reliance on imported high-precision medical devices, while Asia-Pacific faces cost pressures on device manufacturing and distribution. These tariffs are increasing procedure costs and delaying equipment upgrades. However, they are also encouraging local device manufacturing, regional supplier development, and increased investment in domestically produced ophthalmic surgical technologies.
The glaucoma surgery devices market research report is one of a series of new reports from The Business Research Company that provides glaucoma surgery devices market statistics, including glaucoma surgery devices industry global market size, regional shares, competitors with a glaucoma surgery devices market share, detailed glaucoma surgery devices market segments, market trends and opportunities, and any further data you may need to thrive in the glaucoma surgery devices industry. This glaucoma surgery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The glaucoma surgery devices market size has grown rapidly in recent years. It will grow from $2.13 billion in 2025 to $2.44 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to rising prevalence of glaucoma disorders, increased ophthalmic surgical volumes, growing awareness of early glaucoma treatment, expansion of eye care infrastructure, availability of advanced surgical instruments.
The glaucoma surgery devices market size is expected to see rapid growth in the next few years. It will grow to $4.21 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing aging population, rising adoption of MIGS procedures, growing investments in ophthalmic innovation, increasing demand for outpatient eye surgeries, expansion of advanced glaucoma treatment access. Major trends in the forecast period include increasing adoption of minimally invasive glaucoma surgery devices, rising use of micro-invasive glaucoma implants, growing integration of laser-based treatment systems, expansion of personalized glaucoma treatment approaches, enhanced focus on surgical precision and safety.
The rising prevalence of glaucoma is expected to propel the growth of the glaucoma surgery devices market. Glaucoma is a progressive eye condition that damages the optic nerve and can result in irreversible vision loss if not diagnosed and treated in a timely manner. Devices used for glaucoma surgery are essential for performing these procedures, as they have enhanced the safety, effectiveness, and minimally invasive nature of glaucoma surgeries, thereby increasing demand. For example, in October 2024, The Institute for Health Metrics and Evaluation (IHME), an independent global research center at the University of Washington in Seattle, reported that in 2022, around 4.22 million people in the U.S. were diagnosed with glaucoma, with a prevalence of 1.62% among adults aged 18 and older and 2.56% among those aged 40 and above. Among these individuals, approximately 1.49 million experienced vision-impairing glaucoma, affecting 0.57% of adults 18 and older and 0.91% of adults 40 and above. Thus, the increasing prevalence of glaucoma is driving the expansion of the glaucoma surgery devices market.
Major companies in the glaucoma surgery devices market are focusing on developing innovative solutions, such as direct selective laser trabeculoplasty (DSLT) devices, to provide precise, non-invasive treatment for lowering intraocular pressure in glaucoma patients. Direct selective laser trabeculoplasty (DSLT) devices are advanced ophthalmic tools that use targeted laser energy to treat the eye's drainage system, reducing intraocular pressure without invasive surgery. For example, in February 2025, Alcon Inc., a Switzerland-based eye care device company, launched the Voyager DSLT, the first and only Direct Selective Laser Trabeculoplasty device for treating glaucoma and ocular hypertension. The Voyager(TM) DSLT system is fully automated, delivering 120 laser pulses precisely to the trabecular meshwork via the limbus using advanced eye-tracking technology, without the need for a gonio lens or manual aiming. This innovation improves aqueous outflow to lower intraocular pressure, simplifies the procedure for physicians, and enhances patient comfort. By offering a fast, non-contact, and comfortable treatment, the device can serve as a first-line therapy, potentially reducing reliance on medications while maintaining a strong safety profile.
In July 2024, Alcon Inc., a Switzerland-based eye care device company that provides surgical devices, ophthalmic equipment, and vision-care products, acquired Belkin Vision for an undisclosed amount. Through this acquisition, Alcon aims to expand its glaucoma surgery devices portfolio by incorporating Belkin Vision's Direct Selective Laser Trabeculoplasty (DSLT) platform, enhancing its capabilities in non-incisional glaucoma treatments and strengthening its presence across the glaucoma care continuum. Belkin Vision Ltd, based in Israel, specializes in developing glaucoma surgery devices.
Major companies operating in the glaucoma surgery devices market are Alcon, Johnson & Johnson, Carl Zeiss Meditec AG, Bausch & Lomb, Glaukos Corporation, Sight Sciences, Iridex Corporation, Ellex Medical Lasers, Lumenis, Ziemer Ophthalmic Systems, Nidek, Topcon, BVI, Rheon Medical, New World Medical, Haag-Streit, OptoLight Vision Technology, Katalyst Surgical, Aerie Pharmaceuticals, MicroSurgical Technology, iSTAR Medical
North America was the largest region in the glaucoma surgery devices market in 2025. The regions covered in the glaucoma surgery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the glaucoma surgery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The glaucoma surgery devices market consists of sales ultrasound equipment, tube shunt, and aqueous shunts that help to perform glaucoma surgeries. The market value includes the value of related goods sold by the service provider or included within the service offering. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Glaucoma Surgery Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses glaucoma surgery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for glaucoma surgery devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The glaucoma surgery devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.